Diabetic Macular Edema MarketThe global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...
The 64-week trial is comparing Novartis’ drug with the current formulation of Eylea, while last year the FDA approved a 12-weekly injection formulation of the drug. GlobalData has previously ...
Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have ... followed by injections every eight to 16 weeks for AMD and eight to 12 weeks for DR ...
When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...
From pioneering early industrial gripper systems to mastering Metal Injection Moulding, Germany’s Zimmer Group is today a leader in advanced automation and manufacturing technologies. With operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback